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Introduction: We aimed to evaluate the effect of menopause on skin thickening, as measured by the modified
Rodnan skin score (mRSS), in women with systemic sclerosis (SSc).
Methods: We identified women with either limited or diffuse SSc, aged≥ 18 years, enrolled within the Canadian
Scleroderma Research Group (CSRG) cohort, between 2004 and 2011. As part of the CSRG cohort, subjects undergo
annual assessments with standardized questionnaires and physical examinations. We performed multivariate regression
analyses using generalized estimating equation (GEE) to determine the effect of menopause on the mRSS, adjusting for
relevant covariates including notably age, follow-up time, and disease duration.
Results: We identified 1070 women with SSc, contributing a total of 3546 observations over the study period. Of these
women, at baseline, 65% had limited disease and 35% diffuse disease. In multivariate analyses, we observed a
substantial effect of postmenopausal status on the mean mRSS in women with diffuse disease subtype [−2.62 units,
95% confidence interval (CI) -4.44, −0.80] and significant interaction between menopausal status and disease subtype
(2.04 units, 95% CI 0.20, 3.88). The effect of postmenopausal status on the mean mRSS was smaller in women with
limited SSc (−0.58, 95% CI −1.50, 0.34).
Conclusions: Our results suggest that menopause has a substantial effect on skin thickening in diffuse SSc, with
postmenopausal status being associated with a lower mean mRSS compared to premenopausal status.Introduction
Systemic sclerosis (SSc) is a multisystemic autoimmune
disease, which predominantly affects women (with a
female-to-male ratio of up to 9:1) [1]. Skin thickening is a
defining feature of SSc, which is characterized by excessive
production of extracellular matrix proteins (for example,
collagen, laminin, fibronectin) by fibroblasts, resulting in
skin thickening and internal organ fibrosis [1,2]. Currently,
no therapy with an acceptable toxicity profile has proven
to be effective in the treatment of SSc skin disease [3].
Studies have shown a potential effect of methotrexate, but
they were limited by their small sample size [4,5]. Cyclo-
phosphamide, a potent cytotoxic drug, was observed to
have an effect on skin thickening when used for the* Correspondence: evelyne.vinet@mail.mcgill.ca
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unless otherwise stated.treatment of severe interstitial lung disease [6]. However,
cyclophosphamide can lead to significant adverse effects,
including serious infections, premature gonadal failure
(that is, early menopause), and long-term increased risk of
malignancy [7,8].
Recent experimental evidence suggests that estrogen in-
creases synthesis of extracellular matrix proteins in cul-
tures of SSc skin fibroblasts [9]. Indeed, investigators have
shown that estrogen induced a significant increase of fi-
bronectin, collagen type I, and laminin synthesis in SSc fi-
broblasts compared to untreated fibroblasts. Moreover, an
estrogen-receptor inhibitor (that is, tamoxifen) induced a
significant decrease of these extracellular matrix proteins
in cultures of SSc skin fibroblasts [9].
Menopause, characterized by a low estrogenic state, is
associated with skin thinning, due to decreased extracellu-
lar matrix protein deposition by fibroblasts [10]. Thinning
of the dermis often accompanies aging. However, most
studies suggest that collagen loss is more closely related to
postmenopausal status than chronologic age, reflectingd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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mean decline in dermal collagen of approximately 1 to 2%
per year after menopause [11]. Estrogen supplementation
in postmenopausal women has been shown to increase
skin thickness by increasing skin collagen content [12].
Although SSc most commonly occurs near the end of the
reproductive period and predominantly affects women, no
one has investigated the impact of menopause on skin in-
volvement in women with SSc. Thus, we aimed to evaluate
the effect of menopause on skin thickening, as measured by
the modified Rodnan skin score (mRSS), in women with SSc.
Methods
Subjects
We used previously collected data from women with either
limited or diffuse SSc, aged ≥18 years, enrolled within the
Canadian Scleroderma Research Group (CSRG) cohort, be-
tween 2004 and 2011. The CSRG cohort is a national pro-
spective cohort recruiting subjects with SSc at 15 sites
across Canada, since 2004. SSc diagnosis in all subjects is
clinically confirmed by a rheumatologist. As part of the
CSRG cohort, subjects undergo annual assessments with
standardized questionnaires (both patient self-reported and
physician-reported) and a physical examination.
Covariates and exposure of interest
We obtained information on baseline characteristics in-
cluding race/ethnicity (defined as white, black, or other),
age at disease onset, and disease duration (since first
non-Raynaud disease manifestation), as well as time-
varying covariates recorded at each annual visit, includ-
ing menopausal status, disease subtype (limited versus
diffuse), smoking (ever versus never smoker), and medi-
cations. Medication exposures were collected by physi-
cians and included information on exposure (current
versus past/never) to oral contraceptive pills (OCP), hor-
mone replacement therapy (HRT), disease-modifying anti-
rheumatic drugs (DMARDs) (that is, d-penicillamine,
methotrexate, leflunomide, and mycophenolate mofetil, as
well as bosentan), and exposure (ever versus never) to
cyclophosphamide. Of note, bosentan was categorized a
priori as a DMARD because observational studies have
shown a potential beneficial effect on skin thickening
[13,14], and cyclophosphamide was evaluated independ-
ently because of its well-known association with premature
gonadal failure (that is, early menopause). The exposure of
interest, menopausal status, was assessed through self-
report, by asking the subject if they had reached menopause
at baseline or since the last follow-up visit if they were pre-
viously premenopausal.
Outcome assessment
The outcome was measured at each annual visit using the
mRSS, a validated measure of skin thickening in SSc [15].In the mRSS, skin thickening is assessed at 17 body sites
by palpation and rated on a scale with values of 0 (nor-
mal), 1 (mild), 2 (moderate) or 3 (severe skin thickening)
[2]. The total skin score is the sum of the individual skin
assessments in the 17 body areas, with a possible range of
0 to 51; the higher the score, the greater the extent and se-
verity of skin thickening.
Statistical analysis
We used descriptive statistics to evaluate the subjects’
characteristics and the association between the different
covariates. We performed univariate and multivariate re-
gression analyses using a generalized estimating equation
(GEE), with each subject serving as a cluster, and assum-
ing an autoregressive correlation structure on the error
terms, to determine the effect of menopause on the mRSS.
The GEE method is an innovative statistical approach,
which judiciously uses longitudinal data by directly relat-
ing changes in the covariate of interest (for example,
menopausal status) in a given subject to changes in the
outcome variable (for example, mRSS) of that same sub-
ject over time. Of note, missing data (present in fewer than
11% of visits) were handled by using multiple imputation.
In the multivariate analyses, in addition to menopausal
status, other relevant covariates (defined above) were evalu-
ated, and included: disease subtype, an interaction term be-
tween menopausal status and disease subtype, time (since
baseline visit), disease duration (at baseline), age at disease
onset, race/ethnicity, smoking, and medication exposures
(that is, OCP, HRT, DMARDs, and cyclophosphamide).
Furthermore, to investigate the effect of menopausal status
on skin thickening in early disease, we conducted a sub-
sample analysis, using the same multivariate model as spe-
cified above, but restricted to women with baseline disease
duration shorter than 5 years.
The McGill University research ethics board approved
this study, as well as the institutional research ethics boards
of each participating site (see the Acknowledgements sec-
tion for complete list). All involved subjects gave informed
consent to participate in the study.
Results
We identified 1,070 women with SSc, contributing a total
of 3,546 observations over the study period, and resulting
in a mean number of visits of 3.3 (SD 3.6). Of these
women, at baseline, 65% had limited disease and 35% dif-
fuse disease (Table 1). At cohort entry, mean age and
mean disease duration were respectively 55.5 (SD 11.7)
and 11.2 (SD 9.6) years, and 72% of subjects had already
reached menopause. Overall, at baseline, the mean mRSS
was 9.6 (SD 9.1), and in pre- and postmenopausal women,
it was respectively 12.0 (SD 10.5) and 8.7 (SD 8.4).
In multivariate analysis, adjusting notably for age,
follow-up time, and disease duration, we demonstrated a
Table 1 Patients’ characteristics at baseline (n = 1,070)
Characteristic Value
Menopausal status, n (%)
Premenopausal 291 (28.1)
Postmenopausal 744 (71.9)
Disease subtype, n (%)
Limited 675 (65.0)
Diffuse 369 (35.0)
Age, mean (SD) 55.5 (11.7)
Disease duration, mean (SD) 11.2 (9.6)








Ever smokers, n (%) 576 (53.8)
Medication exposure, n (%)
Oral contraceptives, current use 21 (2.0)
Hormone replacement therapy, current use 86 (8.2)
DMARDs, current use 183 (17.4)
Cyclophosphamide, ever exposed 85 (8.0)
DMARDs, disease-modifying antirheumatic drugs.
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mRSS in women with diffuse disease subtype (−2.62 units,
95% CI −4.44, −0.80; that is, postmenopausal status being
associated with a lower mean mRSS compared to premeno-
pausal status in women with diffuse disease), and substan-
tial interaction between menopausal status and disease
subtype (2.04 units, 95% CI 0.20, 3.88) (Table 2). In the
presence of interaction between two covariates (for ex-
ample, menopausal status and disease subtype), there is no
longer any unique effect of one interacting variable (for ex-
ample, menopausal status), because its effect depends upon
the value of the other interacting variable (for example, dis-
ease subtype). Thus, as reflected by the multivariate regres-
sion coefficients, and in comparison to the effect seen in
women with diffuse SSc, the effect of postmenopausal sta-
tus on the mean mRSS (compared to premenopausal sta-
tus) was smaller in women with limited SSc (−0.58, 95%
CI −1.50, 0.34) and statistically not significant.
As expected, we observed an important effect of the
diffuse disease subtype on the mRSS compared to the
limited disease subtype, the former being associated
with a higher mean mRSS by 12.10 (95% CI 10.39,
13.81) and 10.06 (95% CI 9.27, 10.85) units in premeno-
pausal and postmenopausal women, respectively. Inaddition, we found a small effect of time since baseline
(0.19 unit, 95% CI 0.04, 0.34) and disease duration at
baseline (−0.05 unit, 95% CI −0.07, −0.03), and a mod-
erate effect of DMARDs (1.08 unit, 95% CI 0.22, 1.94)
on the mean mRSS.
We did not observe an effect of smoking on the mean
mRSS (−0.08 unit, 95% CI −0.71, 0.55) and any significant
confounding of smoking on the effect of menopause
(when comparing the univariate and multivariate effect es-
timates and CI). Moreover, sensitivity analyses using dif-
ferent smoking exposure definitions (that is, defining
exposure alternatively as 1) current, past, or never smoker,
and 2) current or past/never smoker) did not reveal any
further confounding of smoking on the main effect esti-
mate (data not shown).
In the multivariate analysis restricted to women with
early disease (that is, baseline disease duration shorter
than 5 years) (Table 3), we observed a larger effect of
postmenopausal status on the mean mRSS (compared
to premenopausal status) both in women with diffuse
(−3.36 units, 95% CI −5.87, −0.85) and limited SSc
(−1.45, 95% CI −3.21, 0.31), as opposed to the effect es-
timates observed in the overall sample.
Discussion
We found that postmenopausal status in women with dif-
fuse SSc was associated with a substantially lower mean
mRSS (by −2.62 units, 95% CI −4.44, −0.80) compared to
premenopausal status. This effect was independent of age,
follow-up time, and disease duration. Our findings are
supported by previous experimental evidence showing
that estrogen increases extracellular matrix protein pro-
duction in skin fibroblast culture of SSc patients [9]. In
addition, observational studies of healthy women showed
skin thinning in postmenopausal women compared to
women who had not yet reached their menopause [10].
Furthermore, it is well-established that estrogen stimu-
lates normal skin fibroblasts to produce transforming
growth factor-beta 1 (TGF-beta 1), as well as monocytes
and macrophages to produce platelet-derived growth
factor (PDGF). Both TGF-beta 1 and PDGF are key pro-
fibrotic cytokines in SSc skin disease [1,16]. As SSc skin
fibroblasts show increased expression of TGF-beta 1 re-
ceptor and PDGF receptor, estrogen might play a role in
SSc pathogenesis through its stimulatory effect on these
two cytokines.
The effect of postmenopausal status on skin thickening
was smaller in women with limited SSc compared to
women with diffuse SSc, as evidenced by the interaction
term between menopausal status and disease subtype. One
potential explanation for the differential effect of meno-
pause on skin thickening in women with diffuse and limited
SSc might reside in the disease subtypes definition. Indeed,
disease subtypes are defined according to the extent and
Table 2 Univariate and multivariate analyses of covariate effects on the modified Rodnan skin score (n = 1,070)
Covariate Univariate effect estimate (95% CI) Multivariate effect estimate (95% CI)
Menopausal status
Premenopausal Reference Reference
Postmenopausal −2.03 (−3.07, −0.99) −2.62 (−4.44, −0.80)
Disease subtype
Diffuse Reference Reference
Limited −10.45 (−11.21, −9.69) −12.10 (−13.81, −10.39)
Menopause* disease typea 1.90 (0.06, 3.74) 2.04 (0.20, 3.88)
Time since baseline (years) −0.13 (−0.32, 0.06) 0.19 (0.04, 0.34)
Disease duration at baseline (years) −0.14 (−0.18, −0.10) −0.05 (−0.07, −0.03)
Age at disease onset (years) 0.04 (0.01, 0.07) 0.02 (−0.01, 0.05)
Race/ethnicity
White Reference Reference
Black −2.00 (−9.96, 5.96) −4.6 (−10.11, 0.91)
Other 0.66 (−0.73, 2.05) −0.46 (−1.42, 0.50)
Smoking
Never Reference Reference
Ever −0.12 (−1.40, 1.16) −0.08 (−0.71, 0.55)
Oral contraceptive pill
Past/never Reference Reference
Current −0.93 (−4.28, 2.42) −0.60 (−3.03, 1.83)
Hormone replacement therapy
Past/never Reference Reference
Current −0.99 (−3.05, 1.07) −0.43 (−1.74, 0.88)
DMARDsb
Past/never Reference Reference
Current 2.09 (0.94, 3.24) 1.08 (0.22, 1.94)
Cyclophosphamide
Never Reference Reference
Ever 1.56 (−0.23, 3.35) 0.73 (−0.60, 2.06)
aInteraction term between menopausal status and disease subtype. DMARDs, bdisease- modifying antirheumatic drugs.
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subtype skin is affected in the hands, feet, forearms, and/or
face) [17]. Thus, by definition, the mRSS is usually lower in
subjects with limited SSc than in those with diffuse SSc,
with different maximum scores (that is, respectively 27 and
51 units). This might explain at least in part the smaller
(absolute) effect size of menopausal status. Indeed, when
contrasted to the baseline mean mRSS, the (relative) effect
size of menopausal status was comparable between diffuse
and limited subtypes, representing respectively 15% and
10% of the subtype-specific mean baseline mRSS.
As expected and shown in prior studies [2], we ob-
served that disease subtype was the strongest predictor
of skin thickening in our cohort, with diffuse SSc being
associated with a higher mean mRSS of at least 10 units.
We also found more severe skin thickening in womenexposed to DMARDs. However, this is likely to have
reflected confounding by disease severity (also known as
confounding by indication), which occurs when a medi-
cation is preferentially prescribed to a group of patients
with a worse baseline prognosis [18]. Indeed, SSc sub-
jects with rapidly progressing and/or more extensive
skin thickening are more likely to have higher mRSS and
be aggressively treated with DMARDs, potentially result-
ing in a seemingly positive effect of DMARD exposure
on the mRSS.
Although not statistically significant, women exposed to
OCP and HRT appeared to have less skin thickening than
unexposed women. Based on available evidence showing
that exogenous estrogen increases skin thickness in nor-
mal women, we would have expected the opposite [10,12].
Still, this finding could also represent confounding by
Table 3 Multivariate analysis of covariate effects on the
modified Rodnan skin score in a subsample of women





Postmenopausal −3.36 (−5.87, −0.85)
Disease subtype
Diffuse Reference
Limited −13.50 (−16.10, −10.99)
Menopause*disease typeb 1.91 (−0.83, 4.65)
Time since baseline (years) −0.13 (−0.40, 0.14)
Disease duration at baseline (years) −0.47 (−0.98, 0.04)
Age at disease onset (years) 0.04 (0.00, 0.08)
Race/ethnicity
White Reference
Black −0.64 (−2.85, 1.11)
Other −0.87 (−1.42, 0.50)
Smoking
Never Reference
Ever 0.86 (−0.55, 2.15)
Oral contraceptive pill
Past/never Reference
Current −0.78 (−2.15, 0.43)
Hormone replacement therapy
Past/never Reference
Current 0.08 (−2.84, 3.00)
DMARDsc
Past/never Reference
Current 0.10 (−1.61, 1.81)
Cyclophosphamide
Never Reference
Ever −0.33 (−2.31, 1.65)
bInteraction term between menopausal status and disease subtype. DMARDs,
cdisease- modifying antirheumatic drugs.
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skin disease and fewer disease complications (such as pul-
monary hypertension or cardiovascular disease) would be
more likely to be sexually active (and be on OCP) or have
fewer contraindications to OCP and/or HRT.
The magnitude of the effect of postmenopausal status
on the mRSS in women with diffuse SSc is very interest-
ing, considering that menopause occurs in all women and
SSc predominantly affects women. Very few exposures, in-
cluding medications, seem to alter the course of skin
thickening in SSc. The minimally important difference in
the mRSS has been established at 3.2 units, based on a
prior randomized controlled trial of d-penicillamine insubjects with diffuse disease [19]. As the CSRG cohort
is not an inception cohort, women included in our study
had long disease duration. Since it is well-established
that skin thickening progresses more rapidly in early
than in late disease [1,2], inclusion of women with lon-
ger disease duration might have limited our ability to
observe a larger effect of menopausal status on skin
thickening. This was evidenced by our subsample ana-
lysis of women with disease duration shorter than
5 years, showing a larger effect of postmenopausal sta-
tus on the mRSS in both disease subtypes. Notably, the
magnitude of the postmenopausal effect in diffuse SSc
(−3.36 units, 95% CI −5.87, −0.85) exceeded the minim-
ally important difference in the mRSS [19].
Medsger et al. described the natural evolution of skin
thickening in SSc subjects [20]. After rapid skin thickening
progression in the first 5 years of the disease, in limited
SSc, skin thickening slows for a few years to reach a plat-
eau after 10 years of evolution, whereas in diffuse SSc, skin
thickening actually regresses, albeit not to the pre-disease
state [20]. Interestingly, in our study, the effect estimates
for the covariates, time since cohort entry (that is, follow-
up time) and disease duration at baseline, reflected this
evolution/involution. Indeed, time since cohort entry had
an overall positive effect on skin thickening (that is, each
additional year of follow up being associated with an aver-
age increase of 0.19 unit (95% CI 0.04, 0.34)), because with
time skin thickening increases more than it regresses.
However, disease duration at baseline had an overall nega-
tive effect on the mRSS (that is, each additional year of
disease duration at baseline being associated with a lower
mean mRSS by −0.05 unit (95% CI −0.07, −0.03)), as skin
thickness peaks in women with early disease. Moreover,
the negative effect of menopausal status on the mRSS that
was objectivated in our study might explain, at least in
part, the natural plateau and/or involution of skin thicken-
ing reported by Medsger et al., which could have coin-
cided with menopause onset in some subjects [20]. In
addition, we did not find an association between age at
disease onset and skin thickening after accounting for
menopausal status in multivariate analysis, suggesting that
menopausal status might be a better predictor of skin
thickening compared to age at diagnosis.
Our study has some potential limitations. We used the
total mRSS as the outcome measure, which assesses both
the extent and degree of skin thickening. Thus, we could
not distinguish the association between menopausal status
and the extent of skin thickening from the association be-
tween menopausal status and the degree of skin thickening.
In addition, we were unable to definitively demonstrate an
effect of smoking on skin thickening. Previous work from
our group has shown the challenges of appropriately mod-
eling smoking exposure in health outcome analyses of
smoking effect in SSc patients, and how these analyses can
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making the smoking effect-estimate more conservative than
it should be (that is, biasing the effect estimate towards the
null) [21]. Still, this is unlikely to have affected our main
effect-estimate as smoking did not appear to be a strong
confounder of the effect of menopausal status on skin
thickening as shown in the univariate and multivariate ana-
lyses. Another potential limitation is that menopausal status
was ascertained annually by self-report and not confirmed
by any laboratory investigation. However, a previous study
has shown high validity of self-reported menopausal status
and suggested self-report as a sufficiently accurate measure
of menopause in observational studies [22].
Conclusions
Our results suggest that menopause has a substantial ef-
fect on skin thickening in diffuse SSc, with postmeno-
pausal status being associated with a lower mean mRSS
compared to premenopausal status. This effect might be
more pronounced in early disease (that is, baseline dis-
ease duration shorter than 5 years). Our findings should
prompt further research on the role of estrogen on skin
disease progression in SSc.
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